FDA adcomm votes in favor of ARS Pharmaceuticals' EpiPen alternative

Zachary Brennan

Senior Editor

An advisory committee of outside experts to the FDA today voted 16-6 in favor of ARS Pharmaceuticals’ EpiPen alternative for adults (and 16-5 for children …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm votes in favor of ARS Pharmaceuticals' EpiPen alternative

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

FDA ad­comm votes in fa­vor of ARS Phar­ma­ceu­ti­cal­s' EpiPen al­ter­na­tive

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

FDA adcomm votes in favor of ARS Pharmaceuticals' EpiPen alternative

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market